Fundraising Fox
🦊/Companies
Sign in

Inozyme Pharma

Boston, US · Founded 2015 · Delaware corporation · 5 known investors

Find your way into Inozyme Pharma

220 people in our graph share verified history with the Inozyme Pharma team — schools, employers, funds. One of them is your warm intro.

Benedict Evansunlockedknows Axel Bolte · together at University of Cambridge (overlapped)
×4knows the team · via University of Cambridge
×4knows the team · via ETH Zürich
×2knows the team · via University of St.Gallen
knows the team · via The Trout Group
Biotech

Founders & leadership

Inozyme Pharma was founded in 2015 by Axel Bolte.

ABAxel Bolte
Axel BolteinCo-Founder2023–2025Axel Bolte is co-founder and former president and CEO of Inozyme Pharma, a Nasdaq-listed company developing treatments for rare metabolic diseases. He previously worked in healthcare-focused private equity and serves as a board director for both private and public companies.
RD
Reinaldo DiazNamed on SEC filingInvestor at Longitude Capital
JS
Joseph SchlessingerNamed on SEC filing

Board

EM
Edward MathersBoard director
RHRob Hopfner
Rob HopfnerinBoard2019–2025Managing Director at Pivotal Life Sciences
ME
Martin EdwardsBoard director

Investors · 5

Longitude CapitalMenlo Park · $10M – $30M
New Enterprise Associates (NEA)Menlo Park · $200K – $40M
Sanofi VenturesCambridge · $5M
Sofinnova VenturesMenlo Park · $100K – $15M
Pivotal Life SciencesreportedSan Francisco

Reported raises · per SEC filings

Form D private placements

$116.2M disclosed across 2 rounds · 2017–2018

▶$67.4MraisedJun 2020 · 12 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Sarah BhagatDirector
  • Lynne SullivanDirector
  • Reinaldo DiazDirector
  • Rob HopfnerDirector
  • Edward MathersDirector
  • Martin EdwardsDirector
  • Axel BolteExecutive Officer, Director
  • Douglas TrecoDirector
Offering amount
$67.4M
Amount sold
$67.4M
First sale
Nov 2018
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$48.9MraisedNov 2018 · 14 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Axel BolteExecutive Officer, Director
  • Edward MathersDirector
  • Reinaldo DiazDirector
  • Rob HopfnerDirector
  • Martin EdwardsDirector
  • Joseph SchlessingerExecutive Officer, Director
Offering amount
$48.9M
Amount sold
$48.9M
First sale
Jan 2017
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Piper Sandler raises Inozyme Pharma target to $43 from $40 By Investing.cominvesting.com · Nov 2024Inozyme Pharma Raises $67 Million in Series A2 Financing to Develop Therapies for Rare Mineralization Disorders | AP Newsapnews.com · Apr 2019Inozyme Pharma Raises $49 Million to Develop Therapies for Rare Diseases Affecting Soft Tissue and Bone - Global Genesglobalgenes.org · Nov 2017Inozyme Pharma raises $49 million in a Series A financing | Reutersreuters.com · Nov 2017Buy Inozyme Pharma, Inc. Stock – INZY Stock Quote Today & Investment Insights - Public.compublic.com

Frequently asked questions

Who founded Inozyme Pharma?
Inozyme Pharma was founded by Axel Bolte in 2015.
Who are Inozyme Pharma's investors?
Inozyme Pharma's investors include Longitude Capital, New Enterprise Associates (NEA), Sanofi Ventures, Sofinnova Ventures, Pivotal Life Sciences.
How much funding has Inozyme Pharma raised?
Inozyme Pharma has disclosed $116.2M raised across 2 rounds.
Where is Inozyme Pharma headquartered?
Inozyme Pharma is headquartered in Boston, US.